Literature DB >> 10417142

Prior immunity to homologous and heterologous Salmonella serotypes suppresses local and systemic anti-fragment C antibody responses and protection from tetanus toxin in mice immunized with Salmonella strains expressing fragment C.

M Roberts1, A Bacon, J Li, S Chatfield.   

Abstract

We have investigated the effect of preexisting immunity to homologous (Salmonella typhimurium) or heterologous (S. dublin) serotypes of Salmonella on the ability of an attenuated S. typhimurium aroA aroD vector (BRD509) to immunize mice against the heterologous antigen fragment C (FrgC). We studied two strains, BRD847 and BRD937, expressing FrgC carried on plasmids that differ only with respect to the promoter controlling FrgC expression, the nirB promoter in the case of BRD847 and the htrA promoter in the case of BRD937. Mice were preimmunized orally with S. typhimurium BRD509, S. dublin aroA aroD (BRD620), or saline. Forty-four days later, they were immunized orally with BRD847 or BRD937. Prior immunity to S. typhimurium severely depressed the serum immunoglobulin G (IgG) and IgA anti-FrgC response in both BRD847- and BRD937-immunized mice. Mice with existing immunity to S. dublin also had lower IgG anti-FrgC geometric mean titers (GMTs) than did mice preimmunized with saline, but this difference was significant only in the case of mice immunized with BRD937. However, in nonimmune mice or in mice preimmunized with S. typhimurium or S. dublin, the anti-FrgC IgG GMTs were always higher in mice in the BRD937 groups than in the equivalent BRD847 groups. This is reflected in the effect of prior immunity on the ability of oral immunization with BRD847 or BRD937 to protect mice from challenge with a lethal dose of tetanus toxin. All of the mice preimmunized with saline and then immunized with BRD847 or BRD937 survived challenge. Only 20% of the animals immunized with BRD847 and 60% of the mice in the BRD937 group survived tetanus toxin challenge if they were preimmunized with BRD509. Preexisting immunity to S. dublin did not affect the ability of BRD937 to immunize mice against tetanus, but it did reduce the efficiency of BRD847: only 60% percent of the mice survived challenge. The intestinal secretory IgA responses to FrgC were very similar in the BRD847 and BRD937 groups. Prior immunity did depress the IgA anti-FrgC titers but only significantly so in the mice preimmunized with BRD509. These results show that preexisting Salmonella immunity, particularly to homologous serotypes, can severely compromise the ability of live Salmonella vectors to deliver heterologous antigens to the mammalian immune system. However, the results also indicate that this may be overcome by the design of more powerful in vivo expression systems.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417142      PMCID: PMC96658     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene.

Authors:  J J Clare; F B Rayment; S P Ballantine; K Sreekrishna; M A Romanos
Journal:  Biotechnology (N Y)       Date:  1991-05

Review 2.  Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens.

Authors:  L Cárdenas; J D Clements
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

3.  Prior immunologic experience potentiates the subsequent antibody response when Salmonella strains are used as vaccine carriers.

Authors:  J X Bao; J D Clements
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

4.  Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier.

Authors:  N F Fairweather; S N Chatfield; A J Makoff; R A Strugnell; J Bester; D J Maskell; G Dougan
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

Review 5.  Neonatal tetanus in the world today.

Authors:  J P Stanfield; A Galazka
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

6.  Immunity conferred by Aro- Salmonella live vaccines.

Authors:  C E Hormaeche; H S Joysey; L Desilva; M Izhar; B A Stocker
Journal:  Microb Pathog       Date:  1991-02       Impact factor: 3.738

7.  Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.

Authors:  J F Rooney; C Wohlenberg; K J Cremer; B Moss; A L Notkins
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

8.  Oral vaccination against tetanus: comparison of the immunogenicities of Salmonella strains expressing fragment C from the nirB and htrA promoters.

Authors:  M Roberts; J Li; A Bacon; S Chatfield
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

Review 9.  Pathogenesis and immunity in murine salmonellosis.

Authors:  H S Hsu
Journal:  Microbiol Rev       Date:  1989-12

10.  Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine.

Authors:  S N Chatfield; N Fairweather; I Charles; D Pickard; M Levine; D Hone; M Posada; R A Strugnell; G Dougan
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

View more
  14 in total

Review 1.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

2.  Comparison of abilities of Salmonella enterica serovar typhimurium aroA aroD and aroA htrA mutants to act as live vectors.

Authors:  M Roberts; S Chatfield; D Pickard; J Li; A Bacon
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Long-term immunological memory induced by recombinant oral Salmonella vaccine vectors.

Authors:  J J Kohler; L Pathangey; A Hasona; A Progulske-Fox; T A Brown
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

4.  Effect of attenuated Salmonella enterica serovar Typhimurium expressing a Streptococcus mutans antigen on secondary responses to the cloned protein.

Authors:  C Jespersgaard; P Zhang; G Hajishengallis; M W Russell; S M Michalek
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

5.  Effect of preexisting immunity to Salmonella on the immune response to recombinant Salmonella enterica serovar typhimurium expressing a Porphyromonas gingivalis hemagglutinin.

Authors:  J J Kohler; L B Pathangey; S R Gillespie; T A Brown
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

6.  Construction, characterization, and immunogenicity of an attenuated Salmonella enterica serovar typhimurium pgtE vaccine expressing fimbriae with integrated viral epitopes from the spiC promoter.

Authors:  Huaiqing Chen; Dieter M Schifferli
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

7.  Impact of vector priming on the immunogenicity of recombinant Salmonella vaccines.

Authors:  Christofer J Vindurampulle; Stephen R Attridge
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

8.  Vector priming reduces the immunogenicity of Salmonella-based vaccines in Nramp1+/+ mice.

Authors:  Christofer J Vindurampulle; Stephen R Attridge
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

9.  Influence of promoter, gene copy number, and preexisting immunity on humoral and cellular responses to a vectored antigen delivered by a Salmonella enterica vaccine.

Authors:  Manvendra Saxena; Peter J Coloe; Peter M Smooker
Journal:  Clin Vaccine Immunol       Date:  2008-11-12

10.  Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection.

Authors:  Vijayakumar Jawalagatti; Perumalraja Kirthika; Ji-Young Park; Chamith Hewawaduge; John Hwa Lee
Journal:  J Adv Res       Date:  2021-07-22       Impact factor: 10.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.